Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the U.S.
ResearchPosted on rand.org Jun 10, 2021Published in: JAMA, Volume 325, Number 21, pages 2206-2208 (2021). doi: 10.1001/jama.2021.4469
ResearchPosted on rand.org Jun 10, 2021Published in: JAMA, Volume 325, Number 21, pages 2206-2208 (2021). doi: 10.1001/jama.2021.4469
In the US, buprenorphine to treat opioid use disorder can be prescribed only by qualified clinicians. Policy initiatives and advocacy, such as efforts to remove the training requirements required for buprenorphine prescribing, have commonly focused on enlarging the pool of clinicians allowed to prescribe buprenorphine; current legislation under consideration in the US Congress would eliminate these requirements. However, many trained buprenorphine prescribers are not actively prescribing or are treating few patients, and the overall concentration of patient care among prescribers is not well characterized. We quantified the total amount of buprenorphine care delivered by active prescribers and to what extent that varies across specialties.
This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.